Evidence map›Paper›PMID 41749053›Full record

ArticleInternational journal of technology assessment in health care2026

What do HTA agencies need for generating health-related quality of life evidence? Findings from a global survey.

Annushiah Vasan Thakumar, Paula Lorgelly, Louise Longworth, Lucila Rey-Ares, Fredrick Purba, Dominik Golicki, Federico Augustovski, Kim Rand, Rosalie Viney, Nick Bansback and 1 more

Abstract read
In one paragraph

Article in International journal of technology assessment in health care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Annushiah Vasan ThakumarSchool of Pharmacy, Faculty of Health and Medical Sciences, https://ror.org/0498pcx51Taylor's University, Malaysia.ORCID https://orcid.org/0000-0001-7261-1255
Paula LorgellySchool of Population Health and Department of Economics, https://ror.org/03b94tp07University of Auckland, New Zealand.
Louise LongworthArrow Health Economics, UK.
Lucila Rey-AresPatient and Health Impact, Pfizer Argentina, Argentina.
Fredrick PurbaDepartment of Clinical and Health Psychology, Faculty of Psychology, https://ror.org/00xqf8t64Universitas Padjadjaran, Indonesia.
Dominik GolickiDepartment of Experimental and Clinical Pharmacology, https://ror.org/04p2y4s44Medical University of Warsaw, Poland.
Federico AugustovskiHealth Technology Assessment and Health Economics Department, https://ror.org/02nvt4474Institute for Clinical Effectiveness (IECS-CONICETUBA), Argentina.
Kim RandHealth Services Research Unit, Akershus University Hospital, Lørenskog, Norway.
Rosalie VineyCentre for Health Economics Research and Evaluation, https://ror.org/03f0f6041University of Technology Sydney, Australia.
Nick BansbackSchool of Population and Public Health, https://ror.org/03rmrcq20The University of British Columbia, Canada.
Nan LuoSaw Swee Hock School of Public Health, https://ror.org/01tgyzw49National University of Singapore, Singapore.

Funding

EuroQol Research Foundation 1505-RA
6 · The paper itself

Abstract

objectivesThe overall aim is to understand the practices, views, and needs of health technology assessment (HTA) practitioners worldwide regarding the use of health-related quality of life (HRQoL) data for generating cost-effectiveness evidence.

methodsWe invited HTA practitioners in sixty countries to complete an online survey on their perspectives on the measurement and valuation of health. We performed descriptive analyses of the overall sample, examined response differences across six regions, and pooled responses to open-ended questions for content analysis.

resultsA total of 238 individuals from 45 countries completed the survey, with a mean response number per country of 5.28 (SD: 4.45). Most responses came from public sector employees (seventy-two percent), and ninety percent were involved in cost-effectiveness-related work. The top three most frequently used utility instruments were EQ-5D, SF-6D, and EQ-5D-Y, and the elicitation methods were time trade-off, visual analogue scale, and standard gamble. Health-state preferences of the general public from another country were more frequently used than the preferences of the local public. Common data quality issues were poor sample representativeness and a small sample size of utility data. In Asia and Western Europe, the top-voted research priority was developing utility instruments that capture both healthcare and social care impact. In four regions, developing utility instruments for children was the second-highest research priority.

conclusionsThe survey addressed important knowledge gaps regarding current practices in measuring and valuing HRQoL in HTA and provided insights into HTA practitioners' views on instruments, methods, and data-related challenges and needs for generating HRQoL evidence.

Indexed as

Quality of LifeTechnology Assessment, BiomedicalCost-Benefit AnalysisCost-Effectiveness AnalysisHumansSurveys and Questionnairesglobal surveyhealth-related quality of lifehealth-state utilityhealth technology assessmentHT A policyMAUIpreference elicitation

Identifiers

PMID41749053
PMCPMC13071849

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.